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OPEN DATA CAMPAIGN
Open letter: European Medicines Agency should
remove barriers to access clinical trial data
In an open letter to Guido Rasi, director of the European Medicines Agency, the AllTrials campaign
urges the EMA to revise its trial data policy or risk losing the trust of patients and healthcare
professionals
Ben Goldacre research fellow in epidemiology, London School of Hygiene and Tropical Medicine,
Fiona Godlee editor in chief, The BMJ, Carl Heneghan director, Centre for Evidence based Medicine,
Oxford, David Tovey editor in chief, Cochrane Library, Richard Lehman general practitioner,
Oxfordshire, Iain Chalmers coordinator, James Lind Initiative, Virginia Barbour medicine editorial
director, PLOS, Tracey Brown managing director, Sense About Science
Dear Professor Rasi
Hundreds of supporters of the AllTrials campaign (alltrials.net)
contributed last year to the European Medicines Agency’s
consultation on its draft policy “Publication and access to
clinical-trial data.” We welcomed the EMA’s proposals, which
would have seen clinical study reports published proactively
and openly, in line with an agency policy that the information
in those reports should not generally be considered commercially
confidential. We are now concerned that the most recent draft
of the policy (EMA/240810/2013), as shared with some
stakeholders at meetings this month, introduces barriers that
will make it all but useless to independent researchers.
We understand that there are four areas of particular concern:
• Clinical study reports (CSRs) will be available for viewing
only on screen and cannot be saved, downloaded, printed,
copied, annotated, or shared in any way. This will make it
nearly impossible for researchers to usefully scrutinise the
documents. CSRs often contain thousands of pages of
complex information. Research teams need to be able to
share information, and researchers have to be able to print
or copy information such as outcome definitions to make
valid comparisons across studies. Your policy on access
to CSRs as initially proposed could have made a genuine
contribution to medical research. It now risks becoming a
superficial and practically useless gesture.
• The wording of the draft “Redaction Principles” policy is
ambiguous, and where there is ambiguity there is likely to
be excessive redaction. For example,
“statements/descriptions relating to objectives that are not
supportive of a label claim and do not contribute to the
overall benefit/risk evaluation” may be redacted. This
would appear to suggest that any information on off-label
uses of drugs will not be made available. While the
agency’s own use of these documents may be limited to a
decision on one specific use of a treatment, in everyday
clinical practice these same treatments are routinely and
legally used by clinicians outside their marketing
authorisation. This prescribing is based on published
evidence that may be particularly vulnerable to
dissemination bias, since evidence on off-label uses is
frequently excluded from even voluntary codes of practice.
• The “Redaction Principles” policy asks sponsors to submit
two versions of a CSR from each trial: a standard version
(CSR(a)) and a redacted version (CSR(b)).While this might
be driven by a desire to lower the costs of transparency for
the agency, it puts primary responsibility for redacting in
the hands of sponsors. How close CSR(a) is to CSR(b),
and which parts are missing, may never be known to
researchers granted access to CSR(b). Will there be an
audit to explore whether redactions are proportionate or
risk patient safety, and will there be penalties for excessive
redactions?
• The Terms of Use contract contains clauses that seem to
prioritise trial sponsors’ legal rights over researchers’ need
to scrutinise and use information from CSRs to improve
the evidence base for patient care. These supposed rights
given to sponsors have never been established in law and
are currently being debated in court cases in which the
agency is involved. Of greater concern, researchers will
be asked to agree to a clause that allows trial sponsors to
take direct legal action against the researcher for possible
violation of the terms of use. Individual researchers are
therefore being made vulnerable to protracted legal battles
with large companies for infractions to these cumbersome
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rules. Since the rules themselves are poorly specified, these
cases are likely to involve lengthy legal discussion. They
will therefore introduce a new and unpredictable risk of
high legal costs into routine academic work, effectively
chilling researchers’ ability to use information relevant to
patient care.
You have probably heard from some quarters that information
from clinical trials is commercially confidential. We have heard
one drug company lawyer (from AbbVie) even go as far as
claiming that information on adverse events should be kept as
trade secrets. However, some companies and most academic
institutes are throwing off the culture of secrecy and moving
forward. The recently agreed European Clinical Trials Directive
will enshrine the policy that information in CSRs is not generally
commercially confidential in law.
There is no good reason to introduce barriers to access CSRs,
as the agency’s draft policy does. We know you agree that
allowing independent researchers to be free to scrutinise CSRs
will have huge benefits for patients, doctors, pharmacists,
regulators, and researchers and that these will inform treatment
decisions now and decisions about future research.
AllTrials is a campaign for all clinical trials to be registered and
results reported. It is supported by more than 78 000 people and
470 organisations worldwide. The numbers of European citizens
and organisations supporting it are growing every day—and
will continue to grow and press for change.We ask you to revise
the policy to reflect your earlier support for the public interest
in better medicine. We are entering a new era of medicine, one
where medical practice is based on evidence that is openly
available and critically appraised rather than on edicts and
eminence. If the EMA allows its new policy to be based on out
of date attitudes it risks losing the trust of patients, policy
makers, and healthcare professionals. We urge you to revise
your policy to reflect your earlier support for the public interest
in better medicine.
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